文献速递肝病消化道肿瘤与早癌

胰高血糖素样肽-1受体激动剂使用与较低的主要不良肝脏结局风险相关:观察性队列研究的荟萃分析

Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.
PubMed 文献 · Gut · 2025-04-07

该荟萃分析纳入11项回顾性队列研究、共1 467 220例2型糖尿病患者,评估GLP-1RA使用与主要不良肝脏结局(MALOs)的关联。结果显示GLP-1RA使用与MALOs风险降低显著相关(IRR 0.71,95%CI 0.57-0.88),与肝失代偿风险降低相关(IRR 0.70,95%CI 0.52-0.94),与肝细胞癌风险降低的关联未达统计学显著(IRR 0.82,95%CI 0.61-1.11)。

要点

  • GLP-1RA使用与T2D患者MALOs风险降低显著相关(IRR 0.71,95%CI 0.57-0.88)。
  • GLP-1RA使用与肝失代偿风险降低显著相关(IRR 0.70,95%CI 0.52-0.94)。
  • GLP-1RA与肝细胞癌风险降低的关联未达统计学显著(IRR 0.82,95%CI 0.61-1.11)。

核心结论

  • 在2型糖尿病患者中,GLP-1RA使用与肝脏相关并发症和肝失代偿风险降低相关。
  • 这些发现提示GLP-1RA在有益心脏代谢作用之外可能具有预防肝脏相关并发症的作用。

研究设计与样本

  • 系统检索比较GLP-1RA新使用者与其他降糖药物使用者的合格队列研究。
  • 纳入11项回顾性队列研究,汇总数据共1 467 220例2型糖尿病患者(647 903例GLP-1RA新使用者,819 317例非使用者)。
  • 主要结局为MALOs的累积发病率,次要结局包括肝失代偿事件、肝细胞癌和肝脏相关死亡。
  • 采用随机效应模型计算发病率比(IRR)。

主要发现

  • GLP-1RA使用与MALOs风险降低显著相关(IRR 0.71,95%CI 0.57-0.88)。
  • GLP-1RA使用与肝失代偿风险降低显著相关(IRR 0.70,95%CI 0.52-0.94)。
  • GLP-1RA使用与肝细胞癌风险降低的关联未达统计学显著(IRR 0.82,95%CI 0.61-1.11)。
  • 与其他降糖药相比,GLP-1RA在预防MALOs方面优于SGLT2抑制剂(IRR 0.93,95%CI 0.87-0.99)。
  • 与其他降糖药相比,GLP-1RA在预防肝失代偿方面优于DPP-4抑制剂(IRR 0.74,95%CI 0.66-0.83),在预防肝细胞癌方面优于胰岛素治疗(IRR 0.32,95%CI 0.13-0.80)。

关键数值与推荐

  • 主要结局MALOs:GLP-1RA使用组IRR 0.71(95%CI 0.57-0.88)。
  • 肝失代偿:GLP-1RA使用组IRR 0.70(95%CI 0.52-0.94)。
  • 肝细胞癌:GLP-1RA使用组IRR 0.82(95%CI 0.61-1.11)。
  • 与SGLT2抑制剂比较预防MALOs:IRR 0.93(95%CI 0.87-0.99)。
  • 与DPP-4抑制剂比较预防肝失代偿:IRR 0.74(95%CI 0.66-0.83);与胰岛素比较预防肝细胞癌:IRR 0.32(95%CI 0.13-0.80)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liver disease. However, the impact of GLP-1RAs on the long-term risk of major adverse liver-related outcomes (MALOs) remains uncertain. OBJECTIVE: We performed a meta-analysis of observational cohort studies to quantify the magnitude and direction of the association between GLP-1RA use and MALOs in people with type 2 diabetes (T2D). DESIGN: We systematically searched eligible cohort studies comparing GLP-1RA new users versus users of other glucose-lowering medications. The primary outcome was the cumulative incidence rates of MALOs. Secondary outcomes included hepatic decompensation events, hepatocellular carcinoma (HCC) and liver-related mortality. Random-effects models were used to calculate incidence rate ratios (IRRs). RESULTS: 11 retrospective cohort studies with aggregate data on 1 467 220 patients with T2D (647 903 GLP-1RA new users, 819 317 non-users) were included. GLP-1RA use was significantly associated with a lower risk of MALOs (IRR 0.71, 95% CI 0.57 to 0.88) and hepatic decompensation (IRR 0.70, 95% CI 0.52 to 0.94). Association with reduced risk of HCC was also observed (IRR 0.82, 95% CI 0.61 to 1.11). Compared with other antidiabetic medications, GLP-1RAs showed superior effectiveness versus SGLT2 inhibitors in preventing MALOs (IRR 0.93, 95% CI 0.87 to 0.99), versus DPP-4 inhibitors in preventing hepatic decompensation (IRR 0.74, 95% CI 0.66 to 0.83) and versus insulin therapy in preventing HCC (IRR 0.32, 95% CI 0.13 to 0.80). CONCLUSIONS: GLP-1RA use is associated with a lower risk of liver-related complications and hepatic decompensation in people with T2D. These findings suggest a role of GLP-1RAs in preventing liver-related complications beyond their beneficial cardiometabolic effects.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Celsa C, Pennisi G, Tulone A, et al. Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. Gut. 2025. PMID: 40015951. doi:10.1136/gutjnl-2024-334591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。